{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T15:41:55Z","timestamp":1778686915819,"version":"3.51.4"},"reference-count":14,"publisher":"Bentham Science Publishers Ltd.","issue":"5","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["EMIDDT"],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>The  combination  therapy  of  HMG-CoA  reductase  inhibitors  (statins),  which  are  anti-hyperlipidemia agents,  and  fibrates  may  increase  the  risk  of  hepatic  dysfunction  and  myopathy,  so  this  combination  required  careful administration  for  patients.  In  the  present  study,  we  evaluated  the  effects  of  combination  therapy  of  pemafibrate,  a  novel fibrate and statins.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>We  administered  pemafibrate  for  6  months  as  an  add-on  to  statin  therapy  in  27  type  2  diabetes  patients  with dyslipidemia  already  receiving  statins  for  6  months  (combination  group),  and  examined  the  efficacy  and  safety  of  the combination therapy in comparison with a pemafibrate monotherapy group. <\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>In the combination group, a decrease in serum total cholesterol levels was observed after 6\nmonths of pemafibrate treatment compared to baseline, along with an increase in HDL-cholesterol.\nWhile serum triglyceride level was reduced, HbA1c level was elevated in both the groups. Serum\ncreatinine kinase level, which is an indicator of myopathy, was lowered in the combination group.\nIn addition, a decrease in \u03b3-glutamyl transpeptidase, a parameter of hepatic dysfunction, was observed\nin the combination group.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>The  statin-pemafibrate  combination  therapy  in  type  2  diabetes  patients  with  dyslipidemia  improved  lipid metabolism safely without increasing the risk of hepatic dysfunction and myopathy. <\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1871530320999200818135553","type":"journal-article","created":{"date-parts":[[2020,8,21]],"date-time":"2020-08-21T10:33:06Z","timestamp":1598005986000},"page":"919-924","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The Effects of Pemafibrate in Japanese Patients with Type 2 Diabetes Receiving HMG-CoA Reductase Inhibitors"],"prefix":"10.2174","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3225-3577","authenticated-orcid":true,"given":"Masataka","family":"Kusunoki","sequence":"first","affiliation":[{"name":"Research Center of Health, Physical Fitness and Sports, Nagoya University, Furocho, Chikusa-ku, Nagoya 464-8601,Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3158-9706","authenticated-orcid":true,"given":"Takahiko","family":"Sakazaki","sequence":"additional","affiliation":[{"name":"Faculty of Sports and Health Science, Fukui University of Technology, 3-6-1 Gakuen, Fukui 910-8505,Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7566-8257","authenticated-orcid":true,"given":"Kazuhiko","family":"Tsutsumi","sequence":"additional","affiliation":[{"name":"Okinaka Memorial Institute for Medical Research, 2-2-2 Toranomon, Minato-ku, Tokyo 105-8470,Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2893-9744","authenticated-orcid":true,"given":"Tetsuro","family":"Miyata","sequence":"additional","affiliation":[{"name":"Vascular Center, Sanno Medical Center, 8-5-35 Akasaka, Minato-ku, Tokyo 107-0052,Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0113-9368","authenticated-orcid":true,"given":"Yoshiharu","family":"Oshida","sequence":"additional","affiliation":[{"name":"Medical Checkup Center, Minami Seikyo Hospital, 2-204 Minamiohdaka, Midori-ku, Nagoya 459-8540,Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"573","DOI":"10.2337\/diacare.12.8.573","volume":"12","year":"1989","unstructured":"American Diabetes Association. Role of cardiovascular risk factors in prevention and treatment of macrovascular disease in diabetes. Diabetes Care 1989,12(8),573-579","journal-title":"Diabetes Care"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1172\/JCI107331","volume":"52","author":"Goldstein J.L.","year":"1973","unstructured":"Goldstein J.L.; Hazzard W.R.; Schrott H.G.; Bierman E.L.; Motulsky A.G.; Hyperlipidemia in coronary heart disease. I. Lipid levels in 500 survivors of myocardial infarction. J Clin Invest 1973,52(7),1533-1543","journal-title":"J Clin Invest"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.atherosclerosis.2016.08.018","volume":"253","author":"Catapano A.L.","year":"2016","unstructured":"Catapano A.L.; Graham I.; De Backer G.; Wiklund O.; Chapman M.J.; Drexel H.; Hoes A.W.; Jennings C.S.; Landmesser U.; Pedersen T.R.; Reiner \u017d.; Riccardi G.; Taskinen M.R.; Tokgozoglu L.; Verschuren W.M.; Vlachopoulos C.; Wood D.A.; Zamorano J.L.; 2016 ESC\/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention","journal-title":"Atherosclerosis"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.atherosclerosis.2014.02.006","volume":"234","author":"Lamprea-Montealegre J.A.","year":"2014","unstructured":"Lamprea-Montealegre J.A.; Sharrett A.R.; Matsushita K.; Selvin E.; Szklo M.; Astor B.C.; Chronic kidney disease, lipids and apolipoproteins, and coronary heart disease: the ARIC study. Atherosclerosis 2014,234(1),42-46","journal-title":"Atherosclerosis"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.pharmthera.2010.01.008","volume":"126","author":"Chapman M.J.","year":"2010","unstructured":"Chapman M.J.; Redfern J.S.; McGovern M.E.; Giral P.; Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. Pharmacol Ther 2010,126(3),314-345","journal-title":"Pharmacol Ther"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.2337\/diacare.28.6.1419","volume":"28","author":"Koh K.K.","year":"2005","unstructured":"Koh K.K.; Han S.H.; Quon M.J.; Yeal Ahn J.; Shin E.K.; Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia. Diabetes Care 2005,28(6),1419-1424","journal-title":"Diabetes Care"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.atherosclerosis.2010.10.023","volume":"214","author":"Koh K.K.","year":"2011","unstructured":"Koh K.K.; Quon M.J.; Lim S.; Lee Y.; Sakuma I.; Lee Y.H.; Han S.H.; Shin E.K.; Effects of fenofibrate therapy on circulating adipocytokines in patients with primary hypertriglyceridemia. Atherosclerosis 2011,214(1),144-147","journal-title":"Atherosclerosis"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.atherosclerosis.2011.11.018","volume":"220","author":"Koh K.K.","year":"2012","unstructured":"Koh K.K.; Quon M.J.; Shin K.C.; Lim S.; Lee Y.; Sakuma I.; Lee K.; Han S.H.; Shin E.K.; Significant differential effects of omega-3 fatty acids and fenofibrate in patients with hypertriglyceridemia. Atherosclerosis 2012,220(2),537-544","journal-title":"Atherosclerosis"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.atherosclerosis.2016.02.029","volume":"249","author":"Ishibashi S.","year":"2016","unstructured":"Ishibashi S.; Yamashita S.; Arai H.; Araki E.; Yokote K.; Suganami H.; Fruchart J.C.; Kodama T.; Effects of K-877, a novel selective PPAR\u03b1 modulator (SPPARM\u03b1), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial. Atherosclerosis K-877-04 Study Group2016,249,36-43","journal-title":"Atherosclerosis"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.atherosclerosis.2017.03.032","volume":"261","author":"Arai H.","year":"2017","unstructured":"Arai H.; Yamashita S.; Yokote K.; Araki E.; Suganami H.; Ishibashi S.; Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor \u03b1 modulator (SPPARM\u03b1), in combination with statin treatment: Two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia. Atherosclerosis K-877 Study Group2017,261,144-152","journal-title":"Atherosclerosis"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1001\/jama.2012.366","volume":"307","author":"Boekholdt S.M.","year":"2012","unstructured":"Boekholdt S.M.; Arsenault B.J.; Mora S.; Pedersen T.R.; LaRosa J.C.; Nestel P.J.; Simes R.J.; Durrington P.; Hitman G.A.; Welch K.M.; DeMicco D.A.; Zwinderman A.H.; Clearfield M.B.; Downs J.R.; Tonkin A.M.; Colhoun H.M.; Gotto A.M.; Ridker P.M.; Kastelein J.J.; Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA 2012,307(12),1302-1309","journal-title":"JAMA"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"116","DOI":"10.5551\/jat.E560","volume":"15","author":"Shimano H.","year":"2008","unstructured":"Shimano H.; Arai H.; Harada-Shiba M.; Ueshima H.; Ohta T.; Yamashita S.; Gotoda T.; Kiyohara Y.; Hayashi T.; Kobayashi J.; Shimamoto K.; Bujo H.; Ishibashi S.; Shirai K.; Oikawa S.; Saito Y.; Yamada N.; Proposed guidelines for hypertriglyceridemia in Japan with non-HDL cholesterol as the second target. J Atheroscler Thromb 2008,15(3),116-121","journal-title":"J Atheroscler Thromb"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jacl.2017.10.006","volume":"12","author":"Ishibashi S.","year":"2018","unstructured":"Ishibashi S.; Arai H.; Yokote K.; Araki E.; Suganami H.; Yamashita S.; Efficacy and safety of pemafibrate (K-877), a\u00a0selective peroxisome proliferator-activated receptor \u03b1 modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial. J Clin Lipidol K-877 Study Group2018,12(1),173-184","journal-title":"J Clin Lipidol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"5537","DOI":"10.3390\/ijms20225537","volume":"20","author":"Yamashita S.","year":"2019","unstructured":"Yamashita S.; Arai H.; Yokote K.; Araki E.; Matsushita M.; Nojima T.; Suganami H.; Ishibashi S.; Efficacy and safety of pemafibrate, a novel selective peroxisome proliferator-activated receptor \u03b1 modulator (SPPARM\u03b1): pooled analysis of phase 2 and 3 studies in dyslipidemic patients with or without statin combination. Int J Mol Sci 2019,20,5537","journal-title":"Int J Mol Sci"}],"container-title":["Endocrine, Metabolic &amp; Immune Disorders - Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download\/184984","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/184984\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download\/184984","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T06:41:58Z","timestamp":1648449718000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/184984\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":14,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1871530320999200818135553","relation":{},"ISSN":["1871-5303"],"issn-type":[{"value":"1871-5303","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-03-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-19","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}